Dismiss Modal

Patient Information

WakeMed Physician Practices - Pediatric Endocrinology is involved in many different types of diabetes and research projects. Below are brief descriptions of the current studies. To learn more, please call our research coordinator at 919-350-7584.

Type 1 Diabetes: TrialNet

Do you have a family member with Type 1 diabetes?

If the answer is “yes”, then you and your family may have a unique opportunity to join in the fight against diabetes. Researchers from The University of Florida and WakeMed Physician Practices - Pediatric Endocrinology, in collaboration with the National Institutes of Health and Clinical Centers across the country, are seeking a better understanding of how Type 1 diabetes develops. TrialNet researchers are also searching for ways to both prevent and quickly intervene medically in those newly diagnosed with the disease.

For TrialNet’s Natural History Study, researchers are seeking to test family members of people with Type 1 diabetes to determine if these family members show signs of developing the disease.

The clinic is also engaged in other TrialNet sponsored studies

To learn more about TrialNet, go to their website www.diabetestrialnet.org or call our research coordinator at 919-350-7584.

Type 1 Diabetes: NN1218-4101

It has been 20 years since a new short-acting (mealtime) insulin was developed. One of the greatest challenges with currently-available short-acting insulins is the delayed response time. This results in rapid blood sugar rises following meals and poorer glucose control overall.

This study uses a combination of 2 new insulins to try and improve glucose control compared to traditional insulin injection therapy. In particular, the study hopes to find that mealtime dose timing can be more flexible (before or 20 minutes after starting a meal) while still achieving excellent diabetes control.

To learn more about the NN1218-4101 study, call our research coordinator at 919-350-7584.

Type 2 Diabetes: WELKid DM Study

With the growing number of children and adolescents developing Type 2 diabetes, there is a need for alternative treatment options. Welchol (colesevelam) is a medication that is currently FDA approved to treat high cholesterol in both children and adults. Recently it was found to improve blood sugars in adults with Type 2 diabetes, and has been approved to treat Type 2 diabetes in adults. The WELKid DM study is looking at the safety and effectiveness of Welchol (colesevelam) as a treatment for children and adolescents with Type 2 diabetes.

To learn more about the WELKid DM Study, call our research coordinator at 919-350-7584.